HIV vaccine trial launched, 40 years after virus first detected
detected in the United States, a trial for a new vaccine has been launched.The University of Oxford has announced commencement of a phase 1 trial of a newly developed vaccine, HIVconsvX, as part of efforts to finally end the HIV/AIDS epidemic.The vaccine involves two shots, spaced four weeks apart, and is designed to target a “broad range” of HIV variants by inducing the immune system’s T cells to target highly conserved and vulnerable areas of the virus, PharmaTimes reports.Thirteen people will participate in the trial, part of the European Aids Vaccine Initiative, with participants aged between 18 and 65 and not considered at high risk of infection.“An effective HIV vaccine has been elusive for 40 years.